Actively Recruiting
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Led by University of Colorado, Denver · Updated on 2026-05-01
750
Participants Needed
1
Research Sites
518 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The overall goal of this study is to define the phenotype of Interstitial Lung Disease (ILD), and identify factors that predict radiologic progression in those with subclinical RA-ILD, in patients with rheumatoid arthritis (RA). The investigators hypothesize that there are common core elements (e.g. clinical features, genetic variants, and/or biologic markers) between other forms of ILD (e.g. idiopathic pulmonary fibrosis, IPF) and subclinical RA-ILD that places individuals at risk for the development of lung disease.
CONDITIONS
Official Title
Rheumatoid Arthritis Patients at Risk for Interstitial Lung Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 45 years old or older
- Diagnosis of rheumatoid arthritis using the 2010 American College of Rheumatology criteria
You will not qualify if you...
- Unable to give informed consent
- Pregnant women
- History of interstitial lung disease
- Evidence of other causes of diffuse lung disease such as infection, drug toxicity, or other autoimmune processes
- Age under 45 years or over 90 years
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Colorado - Anschutz Medical Campus
Aurora, Colorado, United States, 80045
Actively Recruiting
Research Team
H
Haylie A Lengel
CONTACT
J
Joyce S Lee, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here